These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
257 related articles for article (PubMed ID: 35768005)
1. Standardized 18F-FDG PET/CT radiomic features provide information on PD-L1 expression status in treatment-naïve patients with non-small cell lung cancer. Zhang R; Hohenforst-Schmidt W; Steppert C; Sziklavari Z; Schmidkonz C; Atzinger A; Kuwert T; Klink T; Sterlacci W; Hartmann A; Vieth M; Förster S Nuklearmedizin; 2022 Oct; 61(5):385-393. PubMed ID: 35768005 [TBL] [Abstract][Full Text] [Related]
2. Predictive value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography for PD-L1 expression in non-small cell lung cancer: A systematic review and meta-analysis. Seol HY; Kim YS; Kim SJ Thorac Cancer; 2020 Nov; 11(11):3260-3268. PubMed ID: 32951338 [TBL] [Abstract][Full Text] [Related]
3. [Construction of A Nomogram Prediction Model for PD-L1 Expression in Non-small Cell Lung Cancer Based on 18F-FDG PET/CT Metabolic Parameters]. Hao L; Wang L; Zhang M; Yan J; Zhang F Zhongguo Fei Ai Za Zhi; 2023 Nov; 26(11):833-842. PubMed ID: 38061885 [TBL] [Abstract][Full Text] [Related]
4. The "digital biopsy" in non-small cell lung cancer (NSCLC): a pilot study to predict the PD-L1 status from radiomics features of [18F]FDG PET/CT. Monaco L; De Bernardi E; Bono F; Cortinovis D; Crivellaro C; Elisei F; L'Imperio V; Landoni C; Mathoux G; Musarra M; Pagni F; Turolla EA; Messa C; Guerra L Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3401-3411. PubMed ID: 35403860 [TBL] [Abstract][Full Text] [Related]
6. Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on Takada K; Toyokawa G; Okamoto T; Baba S; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Honda H; Oda Y; Maehara Y Cancer Med; 2017 Nov; 6(11):2552-2561. PubMed ID: 28980429 [TBL] [Abstract][Full Text] [Related]
7. Hu B; Chen W; Zhang Y; Shi H; Cheng D; Xiu Y Ann Nucl Med; 2020 May; 34(5):322-328. PubMed ID: 32130663 [TBL] [Abstract][Full Text] [Related]
8. Assessing PD-L1 Expression Level by Radiomic Features From PET/CT in Nonsmall Cell Lung Cancer Patients: An Initial Result. Jiang M; Sun D; Guo Y; Guo Y; Xiao J; Wang L; Yao X Acad Radiol; 2020 Feb; 27(2):171-179. PubMed ID: 31147234 [TBL] [Abstract][Full Text] [Related]
9. Association between Zhao L; Liu J; Wang H; Shi J Br J Radiol; 2021 Mar; 94(1119):20200397. PubMed ID: 33492995 [TBL] [Abstract][Full Text] [Related]
10. The correlation between PD-L1 expression and metabolic parameters of Xu X; Li J; Yang Y; Sang S; Deng S Clin Imaging; 2022 Sep; 89():120-127. PubMed ID: 35797878 [TBL] [Abstract][Full Text] [Related]
11. Utility of CT radiomics for prediction of PD-L1 expression in advanced lung adenocarcinomas. Yoon J; Suh YJ; Han K; Cho H; Lee HJ; Hur J; Choi BW Thorac Cancer; 2020 Apr; 11(4):993-1004. PubMed ID: 32043309 [TBL] [Abstract][Full Text] [Related]
12. Combining PD-L1 Expression and Standardized Uptake Values in FDG-PET/CT Can Predict Prognosis in Patients With Resectable Non-Small-Cell Lung Cancer. Miyazawa T; Otsubo K; Sakai H; Kimura H; Chosokabe M; Morikawa K; Furuya N; Marushima H; Kojima K; Mineshita M; Koike J; Saji H Cancer Control; 2021; 28():10732748211038314. PubMed ID: 34384268 [TBL] [Abstract][Full Text] [Related]
13. Relationship between SP142 PD-L1 Expression and Zhao L; Liu J; Shi J; Wang H Contrast Media Mol Imaging; 2020; 2020():2010924. PubMed ID: 32765198 [TBL] [Abstract][Full Text] [Related]
14. A Machine Learning Approach Using PET/CT-based Radiomics for Prediction of PD-L1 Expression in Non-small Cell Lung Cancer. Lim CH; Koh YW; Hyun SH; Lee SJ Anticancer Res; 2022 Dec; 42(12):5875-5884. PubMed ID: 36456151 [TBL] [Abstract][Full Text] [Related]
15. Association Between PD-L1 Expression and Metabolic Activity on Takada K; Toyokawa G; Tagawa T; Kohashi K; Akamine T; Takamori S; Hirai F; Shoji F; Okamoto T; Oda Y; Maehara Y Anticancer Res; 2017 Dec; 37(12):7073-7082. PubMed ID: 29187498 [TBL] [Abstract][Full Text] [Related]
16. A Novel Approach Using FDG-PET/CT-Based Radiomics to Assess Tumor Immune Phenotypes in Patients With Non-Small Cell Lung Cancer. Zhou J; Zou S; Kuang D; Yan J; Zhao J; Zhu X Front Oncol; 2021; 11():769272. PubMed ID: 34868999 [TBL] [Abstract][Full Text] [Related]
17. Radiomics study for predicting the expression of PD-L1 in non-small cell lung cancer based on CT images and clinicopathologic features. Sun Z; Hu S; Ge Y; Wang J; Duan S; Song J; Hu C; Li Y J Xray Sci Technol; 2020; 28(3):449-459. PubMed ID: 32176676 [TBL] [Abstract][Full Text] [Related]
18. The Value of Vekens K; Everaert H; Neyns B; Ilsen B; Decoster L Clin Lung Cancer; 2021 Sep; 22(5):432-440. PubMed ID: 33879398 [TBL] [Abstract][Full Text] [Related]
19. Automated PD-L1 status prediction in lung cancer with multi-modal PET/CT fusion. Da-Ano R; Andrade-Miranda G; Tankyevych O; Visvikis D; Conze PH; Rest CCL Sci Rep; 2024 Jul; 14(1):16720. PubMed ID: 39030240 [TBL] [Abstract][Full Text] [Related]
20. Developing a primary tumor and lymph node 18F-FDG PET/CT-clinical (TLPC) model to predict lymph node metastasis of resectable T2-4 NSCLC. Wang M; Liu L; Dai Q; Jin M; Huang G J Cancer Res Clin Oncol; 2023 Jan; 149(1):247-261. PubMed ID: 36565319 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]